45813-02-3

Basic information

• Product Name: 1-Methyl-4-prop-2-ynyl-piperazine
• Synonyms: 1-Methyl-4-prop-2-ynyl-piperazine;Piperazine, 1-Methyl-4-(2-propynyl)-;1-methyl-4-(2-propyn-1-yl)Piperazine
• CAS NO: 45813-02-3
• Molecular Formula: C₈H₁₄N₂
• Molecular Weight: 138.21
• Product Categories: pharmacetical
• Mol File: 45813-02-3.mol
• Article Data: 41

Chemical Properties

• Boiling Point: 185.892°C at 760 mmHg
• Flash Point: 59.377°C
• Appearance: /
• Density: 0.944g/cm³
• Vapor Pressure: 0.681mmHg at 25°C
• Refractive Index: 1.487
• PKA: 7.46±0.10(Predicted)
• CAS DataBase Reference: 1-Methyl-4-prop-2-ynyl-piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Methyl-4-prop-2-ynyl-piperazine(45813-02-3)
• EPA Substance Registry System: 1-Methyl-4-prop-2-ynyl-piperazine(45813-02-3)

Safety Data

• Hazardous Substances Data: 45813-02-3(Hazardous Substances Data)

Usage

Description

1-Methyl-4-prop-2-ynyl-piperazine is a chemical compound with the formula C9H16N2. It is a derivative of piperazine, a heterocyclic amine with a six-membered ring containing two nitrogen atoms. 1-Methyl-4-prop-2-ynyl-piperazine is known for its potential as a building block in organic chemistry and its applications in the synthesis of pharmaceuticals and agrochemicals.

Uses

Used in Pharmaceutical and Agrochemical Industries:
1-Methyl-4-prop-2-ynyl-piperazine is used as a building block in the synthesis of various pharmaceuticals and agrochemicals due to its versatile chemical structure and reactivity.
Used in Central Nervous System Disorders Treatment:
1-Methyl-4-prop-2-ynyl-piperazine is used as a potential treatment for central nervous system disorders, leveraging its neuroprotective properties to support the health and function of the nervous system.
Used in Medicinal Chemistry Research:
1-Methyl-4-prop-2-ynyl-piperazine is used as a precursor in the synthesis of other biologically active compounds, making it an important chemical in the field of medicinal chemistry for the development of new therapeutic agents.

InChI:InChI=1/C8H14N2/c1-3-4-10-7-5-9(2)6-8-10/h1H,4-8H2,2H3

Upstream product

• 109-01-3 1-methyl-piperazine 
• 624-65-7 2-propynyl chloride 
• 107-14-2 chloroacetonitrile 
• 106-96-7 propargyl bromide 
• 50422-36-1 1-(2-bromo-allyl)-4-methyl-piperazine 

Downstream Products

• 700844-87-7 4-[ (2, 4-dichloro-5-methoxyphenyl) amino]-2-[3-(4-methylpiperazin-1-yl) prop-1-ynyl] thieno [2,3-b] pyridine-5-carbonitrile 
• 700844-93-5 2-[3-(4-methylpiperazin-1-yl) prop-1-ynyl]-7-[ (3, 4,5-trimethoxyphenyl) amino] thieno [3,2-b] pyridine-6-carbonitrile 
• 872513-36-5 (2,4-difluoro-phenyl)-(3-{2-methoxy-5-[3-(4-methyl-piperazin-1-yl)-prop-1-ynyl]-phenyl}-1H-pyrazolo-[3,4-d]pyrimidin-6-yl)-amine 
• 1215011-29-2 2,6-dichloro-4-[3-(4-methyl-piperazin-1-yl)-propyl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-benzenesulfonamide 
• 1215011-34-9 4-[3-(4-methylpiperazin-1-yl)-prop-1-ynyl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide 

Relevant articles and documents

Discovery of fast-acting dual-stage antimalarial agents by profiling pyridylvinylquinoline chemical space via copper catalyzed azide-alkyne cycloadditions

To identity fast-acting, multistage antimalarial agents, a series of pyridylvinylquinoline-triazole analogues have been synthesized via CuAAC. Most of the compounds display significant inhibitory effect on the drug-resistant malarial Dd2 strain at low submicromolar concentrations. Among the tested analogues, compound 60 is the most potent molecule with an EC50 value of 0.04 ± 0.01 μM. Our current study indicates that compound 60 is a fast-acting antimalarial compound and it demonstrates stage specific action at the trophozoite phase in the P. falciparum asexual life cycle. In addition, compound 60 is active against both early and late stage P. falciparum gametocytes. From a mechanistic perspective, compound 60 shows good activity as an inhibitor of β-hematin formation. Collectively, our findings suggest that fast-acting agent 60 targets dual life stages of the malarial parasites and warrant further investigation of pyridylvinylquinoline hybrids as new antimalarials.

1,5,7-TRISUBSTITUTED ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN MEDICINES

The present disclosure relates to 1,5,7-trisubstituted isoquinoline derivatives, their preparation and pharmaceutical use. In particular, the present disclosure discloses a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and a preparation method and use thereof. The definitions of the groups in the formula can be found in the specification and claims.

Design, synthesis and biological activities of novel pleuromutilin derivatives with a substituted triazole moiety as potent antibacterial agents

A series of novel pleuromutilin derivatives possessing 1,2,3-triazole moieties were synthesized via click reactions under mild conditions. The in vitro antibacterial activities of these derivatives against 4 strains of S. aureus (MRSA ATCC 43300, ATCC 29213, AD 3, and 144) and 1 strain of E. coli (ATCC 25922) were tested by the broth dilution method. The majority of the synthesized derivatives displayed potent antibacterial activities against MRSA (MIC = 0.125–2 μg/mL). It was also found that most compounds had no significant inhibitory effect on the proliferation of RAW264.7 cells at the concentration of 8 μg/mL. Among these derivatives, compound 32 (～1.71 log10 CFU/g) containing dimethylamine group side chain displayed more effective than tiamulin (～0.77 log10 CFU/g) at the dose of 20 mg/kg in reducing MRSA load in thigh infected mice. Additionally, compound 32 (the survival rate was 50%) also displayed superior in vivo efficacy to that of tiamulin (the survival rate was 20%) in the mouse systemic model. Structure-activity relationship (SAR) studies resulted in compound 32 with the most potent in vitro and in vivo antibacterial activity among the series. Moreover, compound 32 was evaluated in CYP450 inhibition assay and showed moderate in vitro inhibition of CYP3A4 (IC50 = 6.148 μM).